C
Carl G. Kardinal
Researcher at Mayo Clinic
Publications - 42
Citations - 4488
Carl G. Kardinal is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Chemotherapy & Regimen. The author has an hindex of 23, co-authored 42 publications receiving 4401 citations. Previous affiliations of Carl G. Kardinal include Ochsner Health System.
Papers
More filters
Journal ArticleDOI
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines*
Thomas J. Smith,Howard Ozer,Langdon L. Miller,Charles A. Schiffer,Rodger J. Winn,James R. Anderson,Paul N. Anderson,James O. Armitage,Stacey Beckhardt,Charles L. Bennett,Gerald P. Bodey,Jeffrey Crawford,Nancy E. Davidson,George D. Demetri,John T. Hamm,Bruce E. Hillner,Carl G. Kardinal,Mark Levine,John A. Miller,Judith Ochs,Victor M. Santana,Thomas C. Shea,Saroj Vadhan-Raj,James L. Wade,Jane C. Weeks +24 more
Journal ArticleDOI
Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
Bernard Fisher,Ann M. Brown,Nikolay V. Dimitrov,Roger Poisson,Carol K. Redmond,Richard G. Margolese,Bowman D,Norman Wolmark,D L Wickerham,Carl G. Kardinal +9 more
TL;DR: This study and NSABP B-16, which evaluates the worth of AC Therapy in TAM-responsive patients, indicate the merit of 2 months of AC therapy for all positive-node breast cancer patients.
Journal ArticleDOI
Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study
Aminah Jatoi,Harold E. Windschitl,Charles L. Loprinzi,Jeff A. Sloan,S. R. Dakhil,James A. Mailliard,Sarode Pundaleeka,Carl G. Kardinal,Tom R. Fitch,James E. Krook,Paul J. Novotny,Brad Christensen +11 more
TL;DR: In the doses and schedules studied, megestrol acetate provided superior anorexia palliation among advanced cancer patients compared with dronabinol alone, and an improvement in quality of life (QOL) among megestro acetate-treated and combination-treated patients.
Journal ArticleDOI
Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer.
Michael A. Poon,Michael J. O'Connell,Harry S. Wieand,James E. Krook,James B. Gerstner,Loren K. Tschetter,Ralph Levitt,Carl G. Kardinal,James A. Mailliard +8 more
TL;DR: The regimen of 5FU plus low-dose leucovorin has now been shown to offer a statistically significant survival advantage versus 5FU alone and versus5FU plus high-dose MTX, a regimen that had shown promise in earlier trials.
Journal ArticleDOI
Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer.
T R Buroker,Michael J. O'Connell,Harry S. Wieand,James E. Krook,James B. Gerstner,James A. Mailliard,Paul L. Schaefer,Ralph Levitt,Carl G. Kardinal,Dean H. Gesme +9 more
TL;DR: Intensive-course 5FU plus low-dose leucovorin appears to have a superior therapeutic index compared with weekly 5FUplus high-doseLeucovOrin using the dosage administration schedules applied in this study based on similar therapeutic effectiveness, but lower financial cost, and less need for hospitalization to manage chemotherapy toxicity.